A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

The FDA released documents Wednesday giving a look at Pfizer's case for COVID-19 booster shots. The data shows a third dose of Pfizer's shot raised antibody levels with no major safety concerns.

A third dose of the Pfizer/BioNTech Covid-19 vaccine can “strongly” boost protection against the Delta variant – beyond the protection afforded by the standard two doses, new data released ...

Pfizer Inc and BioNTech SE said on Thursday that real-world data from Israel suggests their COVID-19 vaccine is 94% effective in preventing asymptomatic infections, meaning it could significantly ...

Pfizer Inc and BioNTech SE on Tuesday submitted initial trial data for their COVID-19 vaccine in 5-11 year olds and said they would make a formal request to U.S. regulators for emergency use in ...

Pfizer Inc. on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its ...

Scientists welcome the first compelling evidence that a vaccine can prevent COVID-19. But questions remain about how much protection it offers, to whom and for how long.

Pfizer and BioNTech have begun a clinical trial for their Omicron-specific Covid-19 vaccine candidate, they announced in a news release on Tuesday. CNN values your feedback 1.

The drug maker Pfizer said on Wednesday that its coronavirus vaccine was 95 percent effective and had no serious side effects — the first set of complete results from a late-stage vaccine trial ...

Pfizer’s updated results follow Moderna’s report that its Covid-19 vaccine, using similar technology, reduced the risk of Covid-19 by 94.5% in interim results from a 30,000-volunteer clinical ...

Pfizer’s COVID-19 vaccine is 90% effective, preliminary trial data show. The vaccine protects people from getting COVID-19, according to an analysis of 94 cases ...

When the FDA released a 53-page briefing document on Pfizer’s COVID-19 mRNA vaccine candidate yesterday, most readers zeroed in on the shot’s high efficacy in a wide range of demographic groups.